

Verónica Briz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8281071/publications.pdf>

Version: 2024-02-01

54
papers

1,046
citations

430874

18
h-index

454955

30
g-index

56
all docs

56
docs citations

56
times ranked

1526
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trend of hospitalized acute and recurrent hepatitis C in Spain. <i>Annals of Medicine</i> , 2024, 51, 68-68.	3.8	0
2	HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112405.	5.6	3
3	Diarrhoeaâ€causing enteric protist species in intensively and extensively raised pigs (<i>Sus scrofa) Tj ETQq1 1 0.784314 rgBT /Overl	3.0	11
4	Diarrhoeaâ€causing enteric protist species in intensively and extensively raised pigs (<i>Sus scrofa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Transboundary and Emerging Diseases, 2022, 69, .	3.0	3
5	HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy. <i>Scientific Reports</i> , 2022, 12, 5095.	3.3	4
6	Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance. <i>Journal of Clinical Medicine</i> , 2022, 11, 3579.	2.4	2
7	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. <i>Biochemical Pharmacology</i> , 2021, 192, 114666.	4.4	8
8	Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients. <i>Biomedicines</i> , 2021, 9, 1627.	3.2	2
9	Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status. <i>Virulence</i> , 2021, 12, 2919-2931.	4.4	21
10	Nanotechnology: A reality for diagnosis of HCV infectious disease. <i>Journal of Infection</i> , 2020, 80, 8-15.	3.3	18
11	Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2091.	2.4	3
12	Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfecting patients. <i>Scientific Reports</i> , 2020, 10, 11140.	3.3	22
13	Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. <i>Scientific Reports</i> , 2020, 10, 13024.	3.3	1
14	Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000â€“2015): A Nationwide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1607.	2.4	2
15	Protist enteroparasites in wild boar (<i>Sus scrofa ferus</i>) and black Iberian pig (<i>Sus scrofa domesticus</i>) in southern Spain: a protective effect on hepatitis E acquisition?. <i>Parasites and Vectors</i> , 2020, 13, 281.	2.5	23
16	<i>Enterocytozoon bienersi</i> (Microsporidia): Identification of novel genotypes and evidence of transmission between sympatric wild boars (<i>Sus scrofa ferus</i>) and Iberian pigs (<i>Sus scrofa) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.0	11
17	Epidemiological trend of hepatitis C-related liver events in Spain (2000â€“2015): A nationwide population-based study. <i>European Journal of Internal Medicine</i> , 2020, 75, 84-92.	2.2	7
18	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	3.1	14
20	Frecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 262-267.	0.5	2
21	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. <i>Scientific Reports</i> , 2018, 8, 12266.	3.3	16
22	Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018, 36, 262-267.	0.3	0
23	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 2892.	3.3	8
24	Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients. <i>Medicine (United States)</i> , 2016, 95, e3842.	1.0	3
25	NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. <i>PLoS ONE</i> , 2016, 11, e0163197.	2.5	16
26	Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. <i>Aids</i> , 2015, 29, 2155-2159.	2.2	4
27	Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 385-393.	2.9	4
28	Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase. <i>Journal of Molecular Modeling</i> , 2015, 21, 292.	1.8	5
29	Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. <i>Nanoscale</i> , 2015, 7, 14669-14683.	5.6	33
30	Toll-like receptor 8 (TLR8) polymorphisms are associated with non-progression of chronic hepatitis C in HIV/HCV coinfecting patients. <i>Infection, Genetics and Evolution</i> , 2015, 36, 339-344.	2.3	6
31	A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities. <i>PLoS ONE</i> , 2015, 10, e0145239.	2.5	2
32	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. <i>PLoS ONE</i> , 2014, 9, e96307.	2.5	7
33	CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients. <i>Journal of Clinical Virology</i> , 2014, 61, 423-429.	3.1	13
34	Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts. <i>Immunologic Research</i> , 2013, 56, 44-60.	2.9	17
35	Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1. <i>Biopolymers</i> , 2013, 99, 10-21.	2.4	15
36	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. <i>PLoS ONE</i> , 2013, 8, e82718.	2.5	21

#	ARTICLE	IF	CITATIONS
37	Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus. <i>Bioinformatics</i> , 2013, 9, 673-679.	0.5	3
38	Prevalence of Transmitted HIV-1 Drug Resistance Mutations in Children and Adolescents in São Paulo, Brazil. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e255-e257.	2.0	21
39	Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 273-277.	2.0	24
40	Validation of a Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1. <i>Current Medicinal Chemistry</i> , 2012, 19, 5044-5051.	2.4	49
41	Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. <i>HIV Medicine</i> , 2011, 12, 442-446.	2.2	20
42	Short Communication: Evaluation of the Effect of Enfuvirtide in 11 HIV-1 Vertically Infected Pediatric Patients Outside Clinical Trials. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 301-305.	1.1	8
43	LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 563-566.	2.0	8
44	Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227.	1.1	41
45	Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374.	2.2	2
46	Short Communication: Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1078-1082.	1.1	8
47	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.	3.0	54
48	Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410.	3.0	24
49	Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. <i>Aids</i> , 2007, 21, 1487-1490.	2.2	42
50	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 1040-1046.	5.0	43
51	Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. <i>Aids</i> , 2006, 20, 1558-1560.	2.2	20
52	HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367.	2.2	71
53	HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627.	3.0	156
54	Enfuvirtide, the first fusion inhibitor to treat HIV infection. <i>AIDS Reviews</i> , 2005, 7, 139-47.	1.0	77